960化工网
(Hetero-)(arylidene)arylhydrazides as Multitarget-Directed Monoamine Oxidase Inhibitors
AshiquePalakkathondi,JongMinOh,SanalDev,TMRangarajan,SwafvanKaipakasseri,FathimaSahlaKavully,NicolaGambacorta,OrazioNicolotti,HoonKim,BijoMathew
ACS Combinatorial Science Pub Date : 10/13/2020 00:00:00 , DOI:10.1021/acscombsci.0c00136
Abstract
Fourteen (hetero-)(arylidene)arylhydrazide derivatives (ABH1–ABH14) were synthesized, and their inhibitory activities against monoamine oxidases (MAOs) and acetylcholinesterase (AChE) were evaluated. Compound ABH5 most potently inhibited MAO-B with an IC50 value of 0.025 ± 0.0019 μM; ABH2 and ABH3 exhibited high IC50 values as well. Most of the compounds weakly inhibited MAO-A, except ABH5 (IC50 = 3.31 ± 0.41 μM). Among the active compounds, ABH2 showed the highest selectivity index (SI) of 174 for MAO-B, followed by ABH5 (SI = 132). ABH3 and ABH5 effectively inhibited AChE with IC50 values of 15.7 ± 6.52 and 16.5 ± 7.29 μM, respectively, whereas the other compounds were weak inhibitors of AChE. ABH5 was shown to be a reversible competitive inhibitor for MAO-A and MAO-B with Ki values of 0.96 ± 0.19 and 0.024 ± 0.0077 μM, respectively, suggesting that this molecule can be considered as an interesting candidate for further development as a multitarget inhibitor relating to neurodegenerative disorders.
引用文献
Alberga, D; J Chem Inf Model, 10.1021/acs.jcim.8b00698 2019, 59, 586
Anon; LigPrep
Anon; Schrodinger Suite 2018-4 Protein Preparation Wizard
Badavath, V; ACS Med Chem Lett, 10.1021/acsmedchemlett.5b00326 2016, 7, 56
Baek, S; Bioorg Chem, 10.1016/j.bioorg.2018.10.051 2019, 83, 317
Banks, J; J Comput Chem, 10.1002/jcc.20292 2005, 26, 1752
Binda, C; J Med Chem, 10.1021/jm070677y 2007, 50, 5848
Can, N; Molecules, 10.3390/molecules22081381 2017, 22, 1381
Carradori, S; J Med Chem, 10.1021/jm501690r 2015, 58, 6717
Cheung, J; J Med Chem, 10.1021/jm300871x 2012, 55, 10282
Ellman, G; Biochem Pharmacol, 10.1016/0006-2952(61)90145-9 1961, 7, 88
Friesner, R; J Med Chem, 10.1021/jm0306430 2004, 47, 1739
Gaulton, A; Nucleic Acids Res, 10.1093/nar/gkw1074 2017, 45, D945
Hagenow, J; Drug Des, Dev Ther, 10.2147/DDDT.S236586 2020, 14, 371
Harilal, S; J Pharm Pharmacol, 10.1111/jphp.13132 2019, 71, 1370
Herschlag, D; Biochemistry, 10.1021/acs.biochem.8b00217 2018, 57, 3338
Kabir, M; Curr Pharm Des, 10.2174/1381612825666191008103141 2019, 25, 3519
Kavully, F; J Pharm Pharmacol, 10.1111/jphp.13264 2020, 72, 916
Kim, D; ACS Cent Sci, 10.1021/acscentsci.6b00309 2016, 2, 967
Legoabe, L; Eur J Med Chem, 10.1016/j.ejmech.2011.08.036 2011, 46, 5162
Madhavi Sastry, G; J Comput-Aided Mol Des, 10.1007/s10822-013-9644-8 2013, 27, 221
Mangiatordi, G; Eur J Pharm Sci, 10.1016/j.ejps.2017.02.008 2017, 101, 90
Mathew, B; Arch Pharm, 10.1002/ardp.201800309 2019, 352, e1800309
Mathew, B; Arch Pharm, 10.1002/ardp.201900177 2019, 352, e1900177
Mathew, B; Cent Nerv Syst Agents Med Chem, 10.2174/1871524915666151002124443 2016, 16, 120
Mathew, B; ChemMedChem, 10.1002/cmdc.201600122 2016, 11, 1161
Mathew, B; Int J Biol Macromol, 10.1016/j.ijbiomac.2016.05.110 2016, 91, 680
Mathew, B; MedChemComm, 10.1039/C8MD00399H 2018, 9, 1871
Mathew, G; J Biomol Struct Dyn, 10.1080/07391102.2020.1782266 2020
Montaruli, M; Molecules, 10.3390/molecules24122233 2019, 24, 2233
Oh, J; Molecules, 10.3390/molecules25102356 2020, 25, 2356
Parambi, D; Bioorg Chem, 10.1016/j.bioorg.2019.103335 2019, 93, 103335
Reeta; CNS Neurol Disord:Drug Targets, 10.2174/1871527318666190906101326 2019, 18, 643
Shalaby, R; J Enzyme Inhib Med Chem, 10.1080/14756366.2019.1593158 2019, 34, 863
Sinnokrot, M; J Am Chem Soc, 10.1021/ja049434a 2004, 126, 7690
Son, S; Proc Natl Acad Sci U S A, 10.1073/pnas.0710626105 2008, 105, 5739
Turan-Zitouni, G; Molecules, 10.3390/molecules23010113 2018, 23, 113
平台客服
平台客服
平台在线客服